Siemens Healthineers develops medical technology across in vitro and in vivo diagnostics, image-guided therapy and cancer care, including AI diagnostics and digital twins.
Siemens Healthineers develops medical technology spanning in vitro and in vivo diagnostics, image-guided therapy, and cancer care. Its products are designed to support clinical decision-making and to help healthcare providers deliver high-quality care and better patient outcomes. Laboratory-based in vitro diagnostics and in-body in vivo diagnostics anchor the diagnostic portfolio, while imaging-guided technologies support precise treatment delivery and oncology-focused tools address diagnosis and treatment pathways.
The company's technical work extends into artificial intelligence and digital health. It builds AI-powered diagnostic tools and digital twin technology intended to enable personalised treatment, alongside work in precision therapy and clinical decision-making technology. The stated direction of this work is to make care more precise, more personal, and more connected.
Siemens Healthineers employs more than 71,000 people and operates in over 70 countries, serving both urban hospitals and rural communities. It reports more than 125 years of experience in medical technology, with its technologies benefiting millions of patients worldwide.
The company describes its purpose as pioneering breakthroughs in healthcare "for everyone. Everywhere. Sustainably." It states commitments to limiting environmental impact, to improving healthcare access, and to building an inclusive culture in which diverse perspectives inform innovation, pairing engineering excellence with patient-centred impact.
